How Much Bacteriostatic Water for CJC-1295 (No DAC)? (Chart)

Standard Reconstitution Volumes for CJC-1295 (No DAC)

Reconstituting CJC-1295 (No DAC) typically requires adding between 1.0 mL and 2.5 mL of bacteriostatic water per vial, depending on the desired concentration for laboratory assays. Because CJC-1295 (No DAC)—also known as Modified GRF (1-29)—is supplied as a lyophilized powder, adding precise volumes of diluent allows researchers to achieve consistent mass-to-volume ratios. For a standard 2 mg lyophilized vial, adding 1.0 mL of diluent yields a final working concentration of 2.0 mg/mL (2000 mcg/mL), while adding 2.0 mL of diluent reduces the concentration to 1.0 mg/mL (1000 mcg/mL).

When working with larger peptide quantities, such as a 5 mg vial, adding 2.5 mL of bacteriostatic water creates a concentration of 2.0 mg/mL. Utilizing uniform reconstituted concentrations reduces pipetting errors during serial dilutions and micro-dispensing in automated assays. Researchers seeking to automate their calculations across varying vial masses can utilize our interactive reconstitution calculator to quickly derive custom volumetric parameters before beginning benchtop preparation.

Worked Concentration Reference Chart (1 mL, 2 mL, 3 mL, and 5 mL Fills)

To streamline lab operations and prevent mathematical variances across experimental runs, the table below delineates the resulting peptide concentrations for common vial sizes (2 mg and 5 mg) when reconstituted with standard fill volumes of bacteriostatic water (0.9% benzyl alcohol).

For a 2 mg CJC-1295 (No DAC) vial: Reconstituting with 1.0 mL yields 2.00 mg/mL (20 mcg per 10 uL). Reconstituting with 2.0 mL yields 1.00 mg/mL (10 mcg per 10 uL). Reconstituting with 3.0 mL yields 0.67 mg/mL (6.7 mcg per 10 uL). Reconstituting with 5.0 mL yields 0.40 mg/mL (4.0 mcg per 10 uL).

For a 5 mg CJC-1295 (No DAC) vial: Reconstituting with 1.0 mL yields 5.00 mg/mL (50 mcg per 10 uL). Reconstituting with 2.0 mL yields 2.50 mg/mL (25 mcg per 10 uL). Reconstituting with 3.0 mL yields 1.67 mg/mL (16.7 mcg per 10 uL). Reconstituting with 5.0 mL yields 1.00 mg/mL (10 mcg per 10 uL).

Selecting the appropriate fill volume depends on the precision of your analytical tools. Higher concentrations (e.g., 2.0 mg/mL to 5.0 mg/mL) are preferable for high-throughput screening or micro-volume microplate assays, whereas lower concentrations allow greater volumetric resolution when aliquoting manually with standard laboratory micropipettes.

The Arithmetic Behind Reconstitution Calculations

Calculating the working concentration of a reconstituted research peptide follows a straightforward mass-over-volume formula derived from fundamental analytical chemistry principles: Concentration (C) = Mass (m) / Volume (V). When calculating for a 2 mg vial reconstituted with 2.0 mL of diluent, the mathematical expression is: C = 2.0 mg / 2.0 mL = 1.0 mg/mL.

To convert this value into units appropriate for micro-scale in vitro assays, multiply by 1,000 to express the concentration in micrograms per milliliter (mcg/mL) or micrograms per microliter (mcg/uL): 1.0 mg/mL = 1,000 mcg/mL = 1.0 mcg/uL. Consequently, a micropipette volume of 10 uL contains exactly 10 mcg of active sequence.

Understanding these mathematical relationships allows researchers to adjust their diluent volume dynamically depending on assay requirements. If an experimental protocol specifies an addition of 5 mcg per well in a 5 uL volume, the target concentration must be exactly 1.0 mg/mL. Exploring our broader catalog of high-purity research peptides provides access to complementary ligands with detailed molecular weight listings for exact molar calculations.

Physico-Chemical Overview of CJC-1295 (No DAC)

CJC-1295 (No DAC), structurally recognized as Modified GRF (1-29), is a 29-amino-acid synthetic peptide analog of endogenous Growth Hormone-Releasing Hormone (GHRH). It incorporates four amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27) compared to native GHRH (1-29). These structural modifications enhance enzymatic resistance against dipeptidyl peptidase-4 (DPP-IV) cleavage, thereby increasing its biological half-life in vitro compared to unmodified GHRH.

In preclinical laboratory settings, CJC-1295 (No DAC) acts as a selective agonist at the GHRH receptor. It stimulates the cAMP-dependent signaling pathway within pituitary somatotrophs, prompting the pulsatile release of endogenous growth hormone. Unlike continuous long-acting secretagogues, the short half-life of CJC-1295 (No DAC) makes it an ideal reference molecule for investigating natural physiological pulsatility in cellular models. High-grade research material can be obtained directly via our verified CJC-1295 (No DAC) product page.

Comparative Analysis with Related GHRH and Secretagogue Peptides

When establishing experimental controls in somatotroph axis research, investigators frequently compare CJC-1295 (No DAC) against structural analogs and ghrelin receptor agonists. The primary distinction between CJC-1295 (No DAC) and CJC-1295 with DAC lies in the presence of the Drug Affinity Complex (DAC) maleimide reactive group, which covalently binds to circulating albumin to extend systemic half-life from minutes to days. While CJC-1295 with DAC provides continuous GHRH receptor activation, CJC-1295 (No DAC) preserves a episodic, pulsatile secretion profile.

Additionally, comparisons are frequently drawn with Sermorelin, which represents the native 29-amino-acid sequence of GHRH without the four stabilizing amino acid substitutions present in Modified GRF (1-29). In multi-target signaling studies, researchers often co-administer GHRH analogs with selective growth hormone secretagogue receptor (GHSR-1a) agonists such as Ipamorelin to evaluate synergistic growth hormone release across dual receptor pathways.

Laboratory Reconstitution Protocol and Best Practices

Reconstitution must be performed under sterile conditions within a laminar flow hood or clean bench setup to prevent biological contamination. Prior to reconstitution, allow the glass vial containing lyophilized CJC-1295 (No DAC) to equalize to room temperature to minimize condensation formation upon opening.

Clean the rubber septum of the vial using a 70% isopropyl alcohol swab and allow it to air-dry completely. Using a sterile syringe fitted with a low-dead-space needle, draw up the calculated volume of 0.9% bacteriostatic water. Slowly insert the needle through the center of the septum at a 45-degree angle, aiming the stream along the glass wall of the vial. Do not spray the diluent directly onto the delicate lyophilized cake.

Allow the liquid to pool at the base of the vial, allowing the peptide cake to dissolve naturally. Gently swirl the vial in a circular motion until the solution becomes completely clear and colorless. Avoid vigorous shaking, as mechanical shear stress can induce protein aggregation, denaturation, or foam formation.

Aliquoting Guidance and Analytical Storage Protocols

Once fully dissolved, reconstituted CJC-1295 (No DAC) demonstrates reduced thermal stability compared to its solid lyophilized form. To preserve chemical integrity and prevent repeated freeze-thaw cycles—which cause physical shear forces that degrade peptide chains—the reconstituted solution should be aliquoted immediately into single-use micro-centrifuge tubes.

For optimal laboratory storage, aliquot the solution into volumes matching individual experimental batch requirements (e.g., 50 uL to 200 uL working aliquots) using sterile polypropylene tubes. Reconstituted aqueous peptide solutions stored in bacteriostatic water are stable at 2°C to 8°C for up to 28 days. For extended preservation up to several months, frozen storage at -20°C or -80°C is required.

Institutional laboratories requiring bulk allocations for longitudinal studies can review expanded procurement options via our dedicated wholesale laboratory portal.

Quality Verification: COA, Purity, and Endotoxin Standards

Reliable preclinical research depends entirely on the analytical purity and consistency of the underlying chemical reagents. Low-purity compounds introduce confounding variables, such as truncated peptide fragments or chemical impurities, that corrupt receptor binding affinity data and cellular assay outcomes.

PX1 Research ensures that every production batch undergoes strict quality control protocols in ISO 17025 accredited analytical facilities. Every lot is verified via High-Performance Liquid Chromatography (HPLC) to guarantee sequence purity exceeding 99%, while Mass Spectrometry (MS) confirms exact molecular mass identity. Furthermore, every batch undergoes chromogenic LAL testing to verify endotoxin levels remain strictly below threshold limits (<0.01 EU/mg).

Researchers can inspect batch-specific documentation directly through our public certificate of analysis catalog, ensuring complete transparency and compliance with rigorous scientific standards.

Preclinical Mechanisms: Cellular Signaling and IGF-1 Modulation

In vitro and animal model studies indicate that CJC-1295 (No DAC) functions as a potent secretagogue, binding to the extracellular domain of the GHRH receptor on anterior pituitary cells. Preclinical studies suggest that this interaction stimulates adenylate cyclase activity, elevating intracellular cyclic AMP (cAMP) and activating Protein Kinase A (PKA). This signaling cascade prompts both the synthesis and exocytosis of growth hormone vesicles.

Data from rodent models demonstrate that transient pulses of growth hormone induced by Modified GRF (1-29) stimulate hepatic production of Insulin-like Growth Factor 1 (IGF-1). In cellular culture systems, downstream IGF-1 activation plays a key role in accelerating cellular proliferation, protein translation, and tissue repair pathways. Researchers utilize these properties to explore metabolic regulation, skeletal muscle cell differentiation, and extracellular matrix remodeling in non-human models.

Detailed review articles detailing GHRH pathway kinetics and cellular signaling dynamics can be explored within our comprehensive PX1 Research Library.